Recent publications on combined therapy with BRAF and MEK inhibitors (dabrafenib and trametinib respectively) highlighted significant increases in progression-free survival [45], suggesting the importance of these pathways in melanoma biology. This evidence concerns the gene BRAF and melanoma.